TPG (Nasdaq: TPG) has made an investment in K2 Medical Research, a clinical trial site platform focused on central nervous system (CNS) trials for pharma and biotech sponsors.

K2 operates several de novo clinical trial sites across Florida. The company focuses on conducting multi-phase clinical trials in therapeutic areas including Alzheimer’s, psychiatry, and liver disease (MASH), among others. The company has participated in more than 150 studies for over 35 sponsors including AbbVie (NYSE: ABBV), Eisai, Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ) and Roche.